



ASX Announcement

4 October 2012

37 Per Cent Dose Sales Growth in First Quarter

Sirtex Medical Limited (ASX: SRX) today announced dose sales of its SIR-Spheres® microspheres targeted radioactive liver cancer treatment grew 37 per cent for the quarter ended 30 September 2012 compared to the previous corresponding period.

Dose sales in the first quarter of financial year 2013, compared to the same period last year, grew in all regions. The US achieved 42 per cent growth, Europe, Middle East and Africa (EMEA) achieved growth of 26 per cent and Asia Pacific achieved 33 per cent growth. Dose sales are a key measure of the company's business performance and Sirtex has now reported 33 consecutive quarters of sales growth.

Sirtex Chief Executive Officer, Gilman Wong said "These are a pleasing set of numbers. When we measure Sirtex's growth in unit number terms, the last three quarters have been the largest in our history with this quarter being our best. However we should remember in Europe during the first quarter last year we experienced some issues that impacted negatively on our progress. These issues are resolved and we have returned to positive growth.

"We are confident, barring unexpected events, that sales of Sirtex's SIR-Spheres microspheres will continue to grow. The implementation of our *2020Vision* strategy is the prime focus with appropriate investments being made by the company in sales and marketing, clinical studies and research which should ensure Sirtex achieves its future potential."

For further information please contact:

Gilman Wong
CEO Sirtex Medical Limited
(02) 9964 8400

Tim Allerton or Andrew Geddes
CityPR
(02) 9267 4511